Pharmocologic treatment with histone deacetylase 6 inhibitor (ACY-738) recovers Alzheimer's disease phenotype in amyloid precursor protein/presenilin 1 (APP/PS1) mice

Alzheimer's and Dementia: Translational Research and Clinical Interventions

Volumn 1, Issue 3, 2015, Pages 170-181

  Majid, Tabassum ^a   Griffin, Deric ^a   Criss, Zachary ^a   Jarpe, Matthew ^b   Pautler, Robia G ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Acetylon Pharmaceuticals   (United States)

Author keywords

Acetylated tubulin; ACY 738; Alzheimer's disease; Axonal transport; HDAC6; Microtubule; Preclinical; Therapeutic

Indexed keywords

ACY 738; AMYLOID PRECURSOR PROTEIN; HISTONE DEACETYLASE INHIBITOR; PRESENILIN 1; TAU PROTEIN; TUBULIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BRAIN; BRAIN LEVEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEAR; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERACTIVITY; IN VIVO STUDY; LEARNING; LEARNING DISORDER; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NERVE FIBER TRANSPORT; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; WESTERN BLOTTING;

EID: 84951186571     PISSN: None     EISSN: 23528737     Source Type: Journal    
DOI: 10.1016/j.trci.2015.08.001     Document Type: Article

References (51)

1. Alzheimer's Association. Alzheimer's Disease Facts and Figures. Alzheimers Dement. 2014;10:e47-92.
2. M.S. Fiandaca, M.E. Mapstone, A.K. Cheema, and H.J. Federoff The critical need for defining preclinical biomarkers in Alzheimer's disease Alzheimers Dement 10 2014 S196 S212
3. M.D. Carter, G.A. Simms, and D.F. Weaver The development of new therapeutics for Alzheimer's disease Clin Pharmacol Ther 88 2010 475 486
4. M.J. Savage, and D.E. Gingrich Advances in the development of kinase inhibitor therapeutics for Alzheimer's disease Drug Dev Res 70 2009 125 144
5. G.B. Stokin, and L.S. Goldstein Axonal transport and Alzheimer's disease Annu Rev Biochem 75 2006 607 627
6. G.B. Stokin, C. Lillo, T.L. Falzone, R.G. Brusch, E. Rockenstein, S.L. Mount, and et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease Science 307 2005 1282 1288
7. N.M. Kanaan, G.F. Pigino, S.T. Brady, O. Lazarov, L.I. Binder, and G.A. Morfini Axonal degeneration in Alzheimer's disease: When signaling abnormalities meet the axonal transport system Exp Neurol 246 2013 44 53
8. E. Chevalier-Larsen, and E.L. Holzbaur Axonal transport and neurodegenerative disease Biochim Biophys Acta 1762 2006 1094 1108
9. K.R. Brunden, Y. Yao, J.S. Potuzak, N.I. Ferrer, C. Ballatore, M.J. James, and et al. The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies Pharm Res 63 2011 341 351
10. C. Ballatore, K.R. Brunden, D.M. Huryn, J.Q. Trojanowski, V.M. Lee, and A.B. Smith Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies J Med Chem 55 2012 8979 8996
11. A. Bertrand, U. Khan, D.M. Hoang, D.S. Novikov, P. Krishnamurthy, H.B. Rajamohamed Sait, and et al. Non-invasive, in vivo monitoring of neuronal transport impairment in a mouse model of tauopathy using MEMRI Neuroimage 64 2013 693 702
12. K.D. Smith, V. Kallhoff, H. Zheng, and R.G. Pautler In vivo axonal transport rates decrease in a mouse model of Alzheimer's disease Neuroimage 35 2007 1401 1408
13. T. Majid, Y.O. Ali, D.V. Venkitaramani, M.K. Jang, H.C. Lu, and R.G. Pautler In vivo axonal transport deficits in a mouse model of fronto-temporal dementia Neuroimage Clin 4 2014 711 717
14. T. Inoue, T. Majid, and R.G. Pautler Manganese enhanced MRI (MEMRI): Neurophysiological applications Rev Neurosci 22 2011 675 694
15. R. Sharma, E. Buras, T. Terashima, F. Serrano, C.A. Massaad, L. Hu, and et al. Hyperglycemia induces oxidative stress and impairs axonal transport rates in mice PLoS One 5 2010 e13463
16. C.A. Massaad, and R.G. Pautler Manganese-enhanced magnetic resonance imaging (MEMRI) Methods Mol Biol 711 2011 145 174
17. C.A. Massaad, S.K. Amin, L. Hu, Y. Mei, E. Klann, and R.G. Pautler Mitochondrial superoxide contributes to blood flow and axonal transport deficits in the Tg2576 mouse model of Alzheimer's disease PLoS One 5 2010 e10561
18. K.D. Smith, E. Peethumnongsin, H. Lin, H. Zheng, and R.G. Pautler Increased human wildtype tau attenuates axonal transport deficits caused by loss of APP in mouse models Magn Reson Insights 4 2010 11 18
19. C. Cook, J.N. Stankowski, Y. Carlomagno, C. Stetler, and L. Petrucelli Acetylation: A new key to unlock tau's role in neurodegeneration Alzheimers Res Ther 6 2014 29
20. S. Odagiri, K. Tanji, F. Mori, Y. Miki, A. Kakita, H. Takahashi, and et al. Brain expression level and activity of HDAC6 protein in neurodegenerative dementia Biochem Biophys Res Commun 430 2013 394 399
21. L. Zhang, S. Sheng, and C. Qin The role of HDAC6 in Alzheimer's disease J Alzheimers Dis 33 2013 283 295
22. M. Perez, I. Santa-Maria, E. Gomez de Barreda, X. Zhu, R. Cuadros, J.R. Cabrero, and et al. Tau - an inhibitor of deacetylase HDAC6 function J Neurochem 109 2009 1756 1766
23. N. Govindarajan, P. Rao, S. Burkhardt, F. Sananbenesi, O.M. Schlüter, F. Bradke, and et al. Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease EMBO Mol Med 5 2013 52 63
24. L. Zhang, C. Liu, J. Wu, J.J. Tao, X.L. Sui, Z.G. Yao, and et al. Tubastatin A/ACY-1215 improves cognition in Alzheimer's disease transgenic mice J Alzheimers Dis 41 2014 1193 1205
25. S.B. Shah, R. Nolan, E. Davis, G.B. Stokin, I. Niesman, I. Canto, and et al. Examination of potential mechanisms of amyloid-induced defects in neuronal transport Neurobiol Dis 36 2009 11 25
26. T. Onishi, Y. Matsumoto, M. Hattori, Y. Obayashi, K. Nakamura, T. Yano, and et al. Early-onset cognitive deficits and axonal transport dysfunction in P301S mutant tau transgenic mice Neurosci Res 80 2014 76 85
27. M.L. Selenica, L. Benner, S.B. Housley, B. Manchec, D.C. Lee, K.R. Nash, and et al. Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition Alzheimers Res Ther 6 2014 12
28. L. Santo, T. Hideshima, A.L. Kung, J.C. Tseng, D. Tamang, M. Yang, and et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma Blood 119 2012 2579 2589
29. C. D' Ydewalle, J. Krishnan, D.M. Chiheb, P. Van Damme, J. Irobi, A.P. Kozikowski, and et al. HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease Nat Med 17 2011 968 974
30. E. Peethumnongsin, L. Yang, V. Kallhoff-Munoz, L. Hu, A. Takashima, R.G. Pautler, and et al. Convergence of presenilin- and tau-mediated pathways on axonal trafficking and neuronal function J Neurosci 30 2010 13409 13418
31. F. Manuchehrfar, A. Shamloo, and N. Mehboudi Dynamic response of axonal microtubules under suddenly applied end forces Conf Proc IEEE Eng Med Biol Soc 2014 2014 6183 6186
32. C. Medway, and K. Morgan Review: The genetics of Alzheimer's disease; putting flesh on the bones Neuropathol Appl Neurobiol 40 2014 97 105
33. K. Herrup, M.C. Carrillo, D. Schenk, A. Cacace, S. Desanti, R. Fremeau, and et al. Beyond amyloid: Getting real about nonamyloid targets in Alzheimer's disease Alzheimers Dement 9 2013 452 458.e1
34. J. Dai, R.M. Buijs, W. Kamphorst, and D.F. Swaab Impaired axonal transport of cortical neurons in Alzheimer's disease is associated with neuropathological changes Brain Res 948 2002 138 144
35. J.L. Jankowsky, D.J. Fadale, J. Anderson, G.M. Xu, V. Gonzales, N.A. Jenkins, and et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: Evidence for augmentation of a 42-specific gamma secretase Hum Mol Genet 13 2004 159 170
36. W. Huang, P.J. Zhu, S. Zhang, H. Zhou, L. Stoica, M. Galiano, and et al. mTORC2 controls actin polymerization required for consolidation of long-term memory Nat Neurosci 16 2013 441 448
37. A. Sbarbati, L. Calderan, E. Nicolato, P. Marzola, E. Lunati, B. Donatella, and et al. Magnetic resonance imaging of the rat Harderian gland J Anat 201 2002 231 238
38. M.R. Akins, and C.A. Greer Cytoskeletal organization of the developing mouse olfactory nerve layer J Comp Neurol 494 2006 358 367
39. J. Kim, I.Y. Choi, M.L. Michaelis, and P. Lee Quantitative in vivo measurement of early axonal transport deficits in a triple transgenic mouse model of Alzheimer's disease using manganese-enhanced MRI Neuroimage 56 2011 1286 1292
40. J.M. Wagner, B. Hackanson, M. Lübbert, and M. Jung Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy Clin Epigenetics 1 2010 117 136
41. J. Gräff, and L.H. Tsai The potential of HDAC inhibitors as cognitive enhancers Annu Rev Pharmacol Toxicol 53 2013 311 330
42. S. Dallavalle, C. Pisano, and F. Zunino Development and therapeutic impact of HDAC6-selective inhibitors Biochem Pharmacol 84 2012 756 765
43. C. Simões-Pires, V. Zwick, A. Nurisso, E. Schenker, P.A. Carrupt, and M. Cuendet HDAC6 as a target for neurodegenerative diseases: What makes it different from the other HDACs? Mol Neurodegener 8 2013 7
44. Y.M. Sung, T. Lee, H. Yoon, A.M. DiBattista, J.M. Song, Y. Sohn, and et al. Mercaptoacetamide-based class II HDAC inhibitor lowers Aβ levels and improves learning and memory in a mouse model of Alzheimer's disease Exp Neurol 239 2013 192 201
45. J.L. Shaw, and K.T. Chang Nebula/DSCR1 upregulation delays neurodegeneration and protects against APP-induced axonal transport defects by restoring calcineurin and GSK-3β signaling PLoS Genet 9 2013 e1003792
46. S.J. Baloyannis Mitochondrial alterations in Alzheimer's disease J Alzheimers Dis 9 2006 119 126
47. P.J. Hollenbeck, and W.M. Saxton The axonal transport of mitochondria J Cell Sci 118 2005 5411 5419
48. G.B. Stokin, and L.S. Goldstein Linking molecular motors to Alzheimer's disease J Physiol Paris 99 2006 193 200
49. A.V. Kuznetsov Comparison of active transport in neuronal axons and dendrites Math Biosci 228 2010 195 202
50. C. Cook, Y. Carlomagno, T.F. Gendron, J. Dunmore, K. Scheffel, C. Stetler, and et al. Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance Hum Mol Genet 23 2014 104 116
51. M. Noack, J. Leyk, and C. Richter-Landsberg HDAC6 inhibition results in tau acetylation and modulates tau phosphorylation and degradation in oligodendrocytes Glia 62 2014 535 547